Grant of Options

RNS Number : 3801V

Stem Cell Sciences plc

28 May 2008

 



Press Release

28th May 2008

Stem Cell Sciences plc

Grant of Options

Stem Cell Sciences plc, the global biotechnology company focused on the commercialisation of stem cells and stem cell technologies in research and cell-based therapies, announces that on 23rd May 2008, Dr Alastair J. Riddell, Chief Executive Officer, was granted options to acquire 680,484 new Ordinary Shares in the Company at a price of 17 pence per share. 

These options vest over a four year period and the strike price is based upon the average price of the three previous days trading to the grant date of 23rd May 2008. 

Following the above grant, Dr. Riddell holds options over 942,984 shares, which is equal to 3% of the issued share capital.

Approval for the issue of share options was granted by security holders at the Company's AGM dated 15 May 2008. 

- Ends -

For further information, please contact:

Stem Cell Sciences plc (United Kingdom)

Giorgio Reggiani, Company Secretary                [phone]

Notes to Editors

Stem Cell Sciences plc (SCS, AIM:STEM, ASX:STC) is a leading provider of cells and cell culture media to the burgeoning stem cell research market. The successful application of stem cells in both research and clinical applications is reliant on the reproducible supply of pure, fully characterised stem cells and stem cell-derived specialised cells such as nerves and muscle. By providing these products, to the life sciences industry and academia for use in basic research and drug discovery, Stem Cell Sciences has multiple potential revenue streams.

Stem Cell Sciences has multiple industry collaborations, including Millipore Corporation for the marketing and distribution of HEScGRO™, its serum free media for the growth of human embryonic stem cells and Merck & Co for the use of mouse neural stem cell technology for research applications. It recently announced deals with a major pharmaceutical company in the field of diabetes research and with the Myelin Repair Foundation in the USA in neurological research.

To access cutting edge technologies on a rapid and on-going basis, Stem Cell Sciences has built an exceptional network of highly interactive collaborations with academic centres of excellence in the stem cell field. These collaborations have been the source of our founding technologies and continue to provide an expanding pipeline of products and intellectual property that are central to the Company's strategy and success. For further information on the company please visit:  www.stemcellsciences.com

 

END

 

 

RDSIIFVTELITFIT